Inovio Pharmaceuticals Stock Performance
| INO Stock | USD 4.32 0.13 3.10% |
The company retains a Market Volatility (i.e., Beta) of 1.94, which attests to a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Inovio Pharmaceuticals will likely underperform. At this point, Inovio Pharmaceuticals has a negative expected return of -0.58%. Please make sure to check out Inovio Pharmaceuticals' total risk alpha, skewness, as well as the relationship between the Skewness and day median price , to decide if Inovio Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Inovio Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in December 2024. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return 3.1 | Five Day Return 6.67 | Year To Date Return (36.19) | Ten Year Return (96.11) | All Time Return (99.39) |
Last Split Factor 1:12 | Last Split Date 2024-01-25 |
1 | Acquisition by Weiner David B. of 2167 shares of Inovio Pharmaceuticals subject to Rule 16b-3 | 09/27/2024 |
2 | Exelixis Soars 8.6 percent Is Further Upside Left in the Stock | 10/16/2024 |
3 | Acquisition by Benito Simon X of 2167 shares of Inovio Pharmaceuticals subject to Rule 16b-3 | 11/01/2024 |
4 | INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024 | 11/06/2024 |
5 | Inovio Pharmaceuticals Q3 2024 Earnings Preview | 11/13/2024 |
6 | Inovio Pharmaceuticals Q3 2024 Earnings Call Transcript | 11/15/2024 |
7 | Human Papillomavirus Market is Projected to Boost at a Moderate Growth Rate During the Study Period DelveInsight | 11/18/2024 |
8 | Inovio Pharma Stock Slips Ahead of Q3 Earnings Retails Bullish - MSN | 11/20/2024 |
9 | Inovio Pharmaceuticals SWOT analysis stock faces challenges amid pipeline progress | 11/26/2024 |
| Begin Period Cash Flow | 46.3 M |
Inovio |
Inovio Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 643.00 in Inovio Pharmaceuticals on September 1, 2024 and sell it today you would lose (211.00) from holding Inovio Pharmaceuticals or give up 32.81% of portfolio value over 90 days. Inovio Pharmaceuticals is generating negative expected returns assuming volatility of 3.2236% on return distribution over 90 days investment horizon. In other words, 28% of stocks are less volatile than Inovio, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Inovio Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Inovio Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Inovio Pharmaceuticals, and traders can use it to determine the average amount a Inovio Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1791
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INO |
Estimated Market Risk
| 3.22 actual daily | 28 72% of assets are more volatile |
Expected Return
| -0.58 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Inovio Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Inovio Pharmaceuticals by adding Inovio Pharmaceuticals to a well-diversified portfolio.
Inovio Pharmaceuticals Fundamentals Growth
Inovio Stock prices reflect investors' perceptions of the future prospects and financial health of Inovio Pharmaceuticals, and Inovio Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Inovio Stock performance.
| Return On Equity | -0.91 | ||||
| Return On Asset | -0.4 | ||||
| Operating Margin | (329.46) % | ||||
| Current Valuation | 37 M | ||||
| Shares Outstanding | 26.1 M | ||||
| Price To Earning | (5.43) X | ||||
| Price To Book | 1.49 X | ||||
| Price To Sales | 190.51 X | ||||
| Revenue | 832.01 K | ||||
| Gross Profit | (177.39 M) | ||||
| EBITDA | (130.39 M) | ||||
| Net Income | (135.12 M) | ||||
| Cash And Equivalents | 348.13 M | ||||
| Cash Per Share | 1.40 X | ||||
| Total Debt | 30.21 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | 5.15 X | ||||
| Cash Flow From Operations | (124.37 M) | ||||
| Earnings Per Share | (4.43) X | ||||
| Market Capitalization | 112.75 M | ||||
| Total Asset | 172.94 M | ||||
| Retained Earnings | (1.62 B) | ||||
| Working Capital | 110.54 M | ||||
| Current Asset | 171.85 M | ||||
| Current Liabilities | 31.47 M | ||||
About Inovio Pharmaceuticals Performance
By examining Inovio Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Inovio Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Inovio Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 184.88 | 193.18 | |
| Return On Tangible Assets | (0.78) | (0.82) | |
| Return On Capital Employed | (1.04) | (1.09) | |
| Return On Assets | (0.78) | (0.82) | |
| Return On Equity | (1.15) | (1.21) |
Things to note about Inovio Pharmaceuticals performance evaluation
Checking the ongoing alerts about Inovio Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Inovio Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Inovio Pharmaceuticals generated a negative expected return over the last 90 days | |
| Inovio Pharmaceuticals has high historical volatility and very poor performance | |
| Inovio Pharmaceuticals has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the last year's revenue of 832.01 K. Reported Net Loss for the year was (135.12 M) with loss before taxes, overhead, and interest of (177.39 M). | |
| Inovio Pharmaceuticals has about 348.13 M in cash with (124.37 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.4. | |
| Inovio Pharmaceuticals has a frail financial position based on the latest SEC disclosures | |
| Latest headline from investing.com: Inovio Pharmaceuticals SWOT analysis stock faces challenges amid pipeline progress |
- Analyzing Inovio Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Inovio Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Inovio Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Inovio Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Inovio Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Inovio Pharmaceuticals' stock. These opinions can provide insight into Inovio Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inovio Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Inovio Stock, please use our How to Invest in Inovio Pharmaceuticals guide.You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inovio Pharmaceuticals. If investors know Inovio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inovio Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.43) | Revenue Per Share 0.025 | Quarterly Revenue Growth (0.55) | Return On Assets (0.40) | Return On Equity (0.91) |
The market value of Inovio Pharmaceuticals is measured differently than its book value, which is the value of Inovio that is recorded on the company's balance sheet. Investors also form their own opinion of Inovio Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Inovio Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inovio Pharmaceuticals' market value can be influenced by many factors that don't directly affect Inovio Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inovio Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inovio Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inovio Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.